Page 1

EX - 99.12 rcus - ex991_6.htm EX - 99.1 ARCUS BIOSCIENCES Exhibit 99.1 • Arcus Biosciences Reports Second Quarter 2021 Financial Results and Provides Operational Highlights All five clinical - stage molecules continue to advance with six ongoing randomized Phase 2 and Phase 3 studies in major tumor types , including lung , colon , prostate and pancreatic cancer AB521 , a small molecule HIF - 2a inhibitor , expected to enter the clinic in 4Q21 Reported encouraging results from our interim analysis for ARC - 7 providing initial validation of our domvanalimab ( anti - TIGIT ) combinations Presented promising data at ASCO and AACR for etrumadenant ( A2a / A2b adenosine receptor antagonist ) in combination with other agents , providing further clinical evidence supporting the potential of this molecule Enrollment in the randomized portion of the ARC - 8 study evaluating quemliclustat ( small molecule CD73 inhibitor ) in first - line pancreatic cancer remains brisk and is expected to complete by year - end Ended the quarter with $ 805 million of cash and investments - HAYWARD , Calif . – ( BUSINESS WIRE ) – August 5 , 2021 - Arcus Biosciences , Inc. ( NYSE : RCUS ) , an oncology - focused biopharmaceutical company working to create best - in - class cancer therapies , today reported financial results for the second quarter ended June 30 , 2021 and provided operational highlights . Management will host a conference call today , August 5 , 2021 beginning at 1:30 pm PT / 4:30 pm ET . " We have made significant progress advancing our portfolio and partnerships in the first half of 2021 , " said Terry Rosen , Ph.D. , CEO . " We generated additional clinical data for four of our clinical - stage molecules , across trials in lung , colon , prostate , and pancreatic cancers , that continue to support our ongoing randomized studies . We also advanced our Fc - enabled anti - TIGIT antibody into a Phase 1 study and selected our HIF - 2a small molecule to be our sixth clinical - stage molecule , anticipated to enter the clinic by the end of the year . With over $ 800 million of cash and investments as of the end of the second quarter , and our partnership with Gilead , we are confident we can address and pursue the immense need in these patient populations and the corresponding magnitude of the market opportunities . " Anti - TIGIT Program Domvanalimab ( Fc - silent anti - TIGIT antibody ) . Recent Highlights : Arcus continues to enroll our ARC - 7 study and ARC - 10 Phase 3 registrational study as planned , based on encouraging results from the first interim analysis from ARC - 7 , a randomized , three - arm Phase 2 trial evaluating domvanalimab ( dom ) + zimberelimab ( zim ) vs. zim vs. dom + zim + etrumadenant ( etruma ) in first - line PD - L1≥50 % , metastatic non - small cell lung cancer ( NSCLC ) . Data from the zim arm demonstrated activity similar to that of other marketed anti - PD - 1 antibodies in the setting .